Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2019 to Oct 2024
Affymetrix Inc. (NASDAQ:AFFX) announced today the launch
of the Affymetrix UserForum, an online magazine featuring weekly
updates on new technology, analyses, services, and training. The
magazine will help scientists perform fast and successful GeneChip(R)
microarray experiments.
The UserForum provides an interactive community where Affymetrix
customers can learn about new products and services, explore emerging
applications, and share research challenges and success stories. The
website offers feature articles, video interviews, and live web talks
with interactive question-and-answer sessions. Topics covered include
software tools, third-party providers, and collaboration updates, such
as the 500K Control Program.
"Affymetrix microarray users will learn about the very latest
tools and applications that can help them plan and perform their
GeneChip-based research in the lab," said Bronwyn Barnett, managing
editor of UserForum. "The UserForum focuses on the whole product
solution from the initial study design to the final data analysis. The
content will help accelerate discovery by enabling customers to
quickly select the right tools and services for the job."
UserForum is a sister publication to the Affymetrix Microarray
Bulletin (AMB), a print and online magazine featuring interviews with
scientists discussing their most recent discoveries based on
microarray research.
To visit the Affymetrix UserForum and to register for regular
email updates, please visit: www.affymetrix.com/userforum/index.uf.
Current UserForum articles and video interviews include:
Collaboration to Create Control Cohort Databases for Affymetrix
500K Human Mapping Array Set
Affymetrix is collaborating with researchers at the National
Genome Research Network in Germany, GlaxoSmithKline, Erasmus MC, the
Karolinska Institute, and others to create a new publicly available
control cohort database for the Affymetrix 100K and 500K Human Mapping
Array sets.
To watch this UserForum video, please visit:
www.affymetrix.com/userforum/news/collaborations/schreiber.uf
The Broad Institute's Mark Daly Discusses the Haploview Software
Tool for Association Studies
Mark Daly, Ph.D., and his team at the Broad Institute have
developed a new software program, called Haploview, for analyzing
linkage disequilibrium and haplotype patterns in genotype data sets
comprising up to tens of thousands of SNPs in thousands of
individuals.
To watch this UserForum video, please visit:
www.affymetrix.com/userforum/analysis/statistics/daly1.uf
Duke and Affymetrix Sign Five-Year Translational Medicine
Agreement
Duke's Joe Nevins and Geoff Ginsburg outline their formula for
translational medicine success.
To read this UserForum article, please visit:
www.affymetrix.com/userforum/news/collaborations/duke.uf
About AMB
AMB is an online and print magazine published by Affymetrix that
highlights leading microarray research and diagnostic development from
around the world. AMB features interviews by and for scientists,
statisticians and software engineers--one expert interviewing another.
Our goal is to create a forum where this community can discuss
research and share new resources and information. AMB print and video
interviews, as well as archived scientific seminars, can be found at:
www.microarraybulletin.com.
About Affymetrix
Affymetrix scientists invented the world's first microarray in
1989 and began selling the first commercial microarray in 1994. Since
then, Affymetrix GeneChip(R) technology has become the industry
standard in molecular biology research. Affymetrix technology is used
by the world's top pharmaceutical, diagnostic and biotechnology
companies as well as leading academic, government and not-for-profit
research institutes. More than 1,400 systems have been installed
around the world and nearly 4,000 peer-reviewed papers have been
published using the technology. Affymetrix' patented photolithographic
manufacturing process provides the most information capacity available
today on an array, enabling researchers to use a whole-genome approach
to analyzing the relationship between genetics and health. Affymetrix
is headquartered in Santa Clara, Calif., with subsidiaries in Europe
and Asia, as well as manufacturing facilities in Sacramento, Calif.,
and Bedford, Mass. The company has about 1,000 employees worldwide.
For more information about Affymetrix, please visit the company's Web
site at www.Affymetrix.com.
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding
Affymetrix' "expectations," "beliefs," "hopes," "intentions,"
"strategies," or the like. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially for
Affymetrix from those projected, including, but not limited to:
uncertainties relating to the success of the UserForum magazine and
publication initiatives discussed in this press release; risks of the
Company's ability to achieve and sustain higher levels of revenue,
higher gross margins, reduced operating expenses; uncertainties
relating to technological approaches, manufacturing (including risks
related to the Company's ability to achieve hoped-for manufacturing
yields for certain array products, including the ability to identify
and resolve manufacturing problems), product development; personnel
retention; uncertainties related to cost and pricing of Affymetrix
products; dependence on collaborative partners; uncertainties relating
to sole source suppliers; uncertainties relating to FDA and other
regulatory approvals; competition; risks relating to intellectual
property of others and the uncertainties of patent protection and
litigation. These and other risk factors are discussed in Affymetrix'
Form 10-K for the year ended December 31, 2005, and other SEC reports,
including its Quarterly Reports on Form 10-Q for subsequent quarterly
periods. Affymetrix expressly disclaims any obligation or undertaking
to release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in Affymetrix'
expectations with regard thereto or any change in events, conditions
or circumstances on which any such statements are based.
NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered
trademarks owned or used by Affymetrix Inc.